Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Clinical Trial on the Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis
Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Clinical Trial on the Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis
To study the efficacy & safety of Houtou Jianweiling tablet through the non-inferiority clinical trial of Houtou Jianweiling tablet with Omeprazole Enteric-coated tablet in patients with chronic non-atrophic gastritis.
This is a Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Clinical Trial on the Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis.
Inclusion Criteria:
Exclusion Criteria:
(1) Subjects with history of gastric surgery.
(2) Patients with complicated and special types of gastritis, peptic ulcer, hemorrhage, cholecystitis, cholelithiasis, dysplasia of gastric mucosa or pathological diagnosis of suspected malignant change.
(3) Patients with atrophy and/or intestinal metaplasia through pathological examination showed;.
(4) Severe primary diseases associated with cardiovascular, cerebrovascular, lung, liver, kidney and hematopoietic system (above grade II of cardiac function; Cr value above the upper limit of normal value), or serious diseases affecting their survival, such as cancer or AIDS;
(5) Patients who have used Chinese and Western medicine to treat chronic non-atrophic gastritis in the last two weeks;
(6) Subjects with psychiatric disorders or a history of alcohol/drug abuse;
(7) Pregnant women, woman who are preparing for pregnancy, lactating women;
(8) Patients who are allergic constitution or allergic to known ingredients of test drugs;
(9) Those who have participated in or are participating in other drug clinical trials in the past 3 months;
(10) The syndrome differentiation is not clear or there are too many and complicated syndromes for the subjects;
(11) Subjects that researchers do not consider appropriate to participate in clinical trials.
(12) Patients with poor compliance are not allowed to participate in this trial.